Table 1.
Clinical and Demographic Characteristics of the Study Participants
| Mean±SD, n (%) | Genetic Subgroup | Total AIM‐HIGH Study | ||
|---|---|---|---|---|
| Statin+Placebo (n=1020) | Statin+ER Niacin (n=1034) | Statin+Placebo (n=1696) | Statin+ER Niacin (n=1718) | |
| Age, y | 64.0±8.7 | 64.6±8.7 | 63.7±8.7 | 63.7±8.8 |
| Sex, female | 164 (16.1%) | 158 (15.3%) | 251 (14.8%) | 253 (14.7%) |
| Body mass index, kg/m2 | 31.2±5.3 | 31.6±5.7 | 30.9±5.2 | 31.5±5.5a |
| History of myocardial infarction | 556 (54.5) | 554 (53.6) | 955 (56.3) | 968 (56.3) |
| History of stroke | 240 (23.5) | 244 (23.6) | 362 (21.3) | 358 (20.8) |
| History of hypertension | 741 (72.6) | 787 (76.1) | 1189 (70.1) | 1250 (72.8) |
| History of diabetes mellitus | 341 (33.4) | 351 (34.0) | 570 (33.6) | 588 (34.2) |
| Baseline HDL‐C, mg/dL | 35.1±5.6 | 34.6±5.6a | 35.3±5.9 | 34.8±5.9a |
| Baseline LDL‐C, mg/dL | 74.6±22.2 | 73.5±22.0 | 75.8±24.3 | 76.2±25.7 |
| Baseline TC, mg/dL | 146.0±26.8 | 144.8±26.9 | 145.2±26.6 | 145.4±28.2 |
| Baseline TG, (mg/dL), median (IQR) | 162 (133‐215) | 166 (131‐217) | 162 (128‐218) | 164 (127‐218) |
| Baseline lipoprotein (a) (nmol/L), median (IQR) | 32 (13‐118) | 36 (14‐132) | 32.7 (13.1‐122.6) | 36.1 (13.5‐126.6) |
| Change in LDL‐C | −4.5 (−20.5, 13.9) | −9.5 (−28.0, 12.3)a | −4.25 (−20.57, 15.70) | −10.00 (−28.00, 12.68)b |
| Change in HDL‐C | 9.4 (0, 18.8) | 25.0 (11.4 to 39.5)b | 9.09 (0.00, 18.92) | 23.33 (10.34, 39.29)b |
| Change in TC | 0 (−12.0, 11.1) | −5.0 (−16.4, 8.4)b | −0.55 (−11.81, 11.59) | −5.19 (−16.17, 8.00)b |
| Change in TG | −4.4 (−24.6, 20.9) | −29.3 (−48.0, −6.4)b | −5.03 (−25.61, 20.77) | −28.24 (−46.61, −3.13)b |
| Change in Lp(a) | −7.5 (−25.9, 11.3) | −19.7 (−38.5, −0.6) | −7.0 (−25, 13.0) | −20.0 (−39.0, 1.0) |
Change in lipid traits reported as median percentage change from baseline to 1 year (IQR). AIM‐HIGH indicates Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes; ER, extended‐release; HDL‐C, high‐density lipoprotein cholesterol; IQR, interquartile range; LDL‐C, low‐density lipoprotein cholesterol; Lp(a), lipoprotein (a); TC, total cholesterol; TG, triglycerides.
a
P<0.05 compared with placebo group.
b
P<0.0001.